CD274 and hepatocellular carcinoma: In a phase III study, patients with advanced HCC were randomized to receive sorafenib (TKI) 400 mg twice daily or cabozantinib (TKI) 40 mg once daily with atezolizumab (ICI, anti-PD-L1 antibody) 1200 mg every 21-day cycle.